Adequate relief in IBS treatment trials: Corrections to errors stated by Whitehead et al. [1]

American Journal of Gastroenterology

Volumn 101, Issue 12, 2006, Pages 2884-2885

  Mangel, Allen W ^a   Fehnel, Sheri ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CILANSETRON;

CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; IRRITABLE COLON; LETTER; MEDICAL CARE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOMETRY; SYMPTOMATOLOGY;

HUMANS; IRRITABLE BOWEL SYNDROME; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION;

EID: 33845429948     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00867_1.x     Document Type: Letter

References (9)

1. Whitehead WE, Palsson OS, Levy RL. Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006;101:1057-65.
2. Schoenfeld P, Talley NJ. Measuring successful treatment of irritable bowel syndrome: Is "satisfactory relief" enough? Am J Gastroenterol 2006;101:1066-8.
3. Camilleri M, Mayer EA, Drossman DA, et al. Treatment of female irritable bowel syndrome patients with alosetron, a 5HT3-receptor antagonist. Aliment Pharm Ther 1999;13:1149-59.
4. Camilleri M, Northcutt AR, Kong S, et al. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: A randomized, placebo controlled trial. Lancet 2000;335:1035-40.
5. Camilleri M, Chey WY, Mayer EA, et al. Alosetron relieves abdominal pain, and improves abnormal bowel function in female, non-constipated, irritable bowel syndrome patients. Arch Intern Med 2001;161:1733-40.
6. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-51.
7. Mangel AW. Adequate relief as a primary endpoint in irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:879-81.
8. Miner P, Stanton DB, Carter F, et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D); efficacy and safety in a 3 month US study. Am J Gastroenterol 2004;99:S277.
9. Leventer S, Raudibaugh K, Frissora C, et al. The safety and efficacy of dextofisopam in patients with diarrheapredominant or alternating irritable bowel syndrome. Gastroenterology 2005;128(suppl 2):A94.